NKI-AVL, Amsterdam

Amsterdam 1066 CX

0 studies enrolling now · 1 studies all time

What they study most

Castration-Resistant Prostatic Neoplasms

Studies at this site

• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer — Completed